MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- STRIDES SHASUN LIMITED (pharmaceuticals)
- STRIDES SHASUN LIMITED Financial Data
STRIDES PHARMA SCIENCE Fact Sheet (PLLB)
Here is the latest financial fact sheet of STRIDES PHARMA SCIENCE. For more details, see the STRIDES PHARMA SCIENCE quarterly results and STRIDES PHARMA SCIENCE share price and chart. For a sector overview, read our pharmaceuticals sector report.
STRIDES PHARMA SCIENCE Price History
| % ch | % | 1.8 |
| No. of shares | m | 59.65 |
| % ch week | % | -5.9 |
| % ch 1-mth | % | -10.6 |
| % ch 12-mth | % | 3.5 |
| 52 week H/L | Rs | 550.4/341.0 |
STRIDES PHARMA SCIENCE Financials
| No. of Mths Year Ending |
15 Mar-14* |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
5-Yr Chart Click to enlarge
|
|---|
| STRIDES PHARMA SCIENCE EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 1,138 | 1,199 | 1,413 | 1,275 | 1,147 | |
| Low | Rs | 344 | 384 | 848 | 918 | 642 | |
| Sales per share (Unadj.) | Rs | 225.1 | 200.6 | 320.3 | 308.1 | 317.2 | |
| Earnings per share (Unadj.) | Rs | 296.6 | 141.7 | 13.2 | 31.3 | 7.8 | |
| Diluted earnings per share | Rs | 296.2 | 141.7 | 19.8 | 46.9 | 11.8 | |
| Cash flow per share (Unadj.) | Rs | 306.1 | 152.5 | 27.9 | 45.4 | 25.1 | |
| Dividends per share (Unadj.) | Rs | 505.00 | 108.00 | 5.00 | 4.50 | 2.00 | |
| Adj. dividends per share | Rs | 504.32 | 107.95 | 7.49 | 6.75 | 3.00 | |
| Dividend yield (eoy) | % | 68.2 | 13.7 | 0.4 | 0.4 | 0.2 | |
| Book value per share (Unadj.) | Rs | 169.0 | 193.9 | 297.5 | 307.4 | 274.3 | |
| Adj. book value per share | Rs | 168.8 | 193.8 | 445.6 | 460.8 | 411.5 | |
| Shares outstanding (eoy) | m | 59.57 | 59.62 | 89.35 | 89.42 | 89.50 | |
| Bonus/Rights/Conversions | ESOP | ESOP | ESOP | ESOP | ESOP | ||
| Price / Sales ratio | x | 3.3 | 3.9 | 3.5 | 3.6 | 2.8 | |
| Avg P/E ratio | x | 2.5 | 5.6 | 85.5 | 35.1 | 114.0 | |
| P/CF ratio (eoy) | x | 2.4 | 5.2 | 40.5 | 24.2 | 35.7 | |
| Price / Book Value ratio | x | 4.4 | 4.1 | 3.8 | 3.6 | 3.3 | |
| Dividend payout | % | 170.3 | 76.2 | 37.8 | 14.4 | 25.5 | |
| Avg Mkt Cap | Rs m | 44,135 | 47,165 | 100,988 | 98,036 | 80,058 | |
| No. of employees | `000 | 1.5 | 2.0 | 4.7 | 5.8 | 2.5 | |
| Total wages/salary | Rs m | 1,572 | 1,721 | 3,577 | 4,192 | 4,341 | |
| Avg. sales/employee | Rs Th | 8,939.5 | 5,979.3 | 6,102.8 | 4,750.8 | 11,325.8 | |
| Avg. wages/employee | Rs Th | 1,047.9 | 860.3 | 762.7 | 722.7 | 1,731.4 | |
| Avg. net profit/employee | Rs Th | 11,778.3 | 4,225.0 | 251.9 | 482.2 | 280.1 | |
| STRIDES PHARMA SCIENCE INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 13,409 | 11,959 | 28,622 | 27,554 | 28,394 | |
| Other income | Rs m | 602 | 386 | 921 | 1,611 | 941 | |
| Total revenues | Rs m | 14,012 | 12,344 | 29,543 | 29,165 | 29,334 | |
| Gross profit | Rs m | 2,234 | 2,289 | 4,140 | 5,274 | 3,965 | |
| Depreciation | Rs m | 565 | 640 | 1,313 | 1,262 | 1,540 | |
| Interest | Rs m | 1,089 | 474 | 1,682 | 1,831 | 1,962 | |
| Profit before tax | Rs m | 1,183 | 1,560 | 2,067 | 3,792 | 1,403 | |
| Minority Interest | Rs m | -6 | 6 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | -47 | 4 | -168 | |
| Extraordinary Inc (Exp) | Rs m | 19,736 | 8,361 | -414 | -364 | -436 | |
| Tax | Rs m | 3,245 | 1,476 | 425 | 634 | 97 | |
| Profit after tax | Rs m | 17,667 | 8,450 | 1,181 | 2,797 | 702 | |
| Gross profit margin | % | 16.7 | 19.1 | 14.5 | 19.1 | 14.0 | |
| Effective tax rate | % | 274.3 | 94.6 | 20.5 | 16.7 | 6.9 | |
| Net profit margin | % | 131.8 | 70.7 | 4.1 | 10.2 | 2.5 | |
| STRIDES PHARMA SCIENCE BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 13,086 | 14,447 | 35,149 | 37,918 | 24,836 | |
| Current liabilities | Rs m | 7,074 | 10,022 | 18,920 | 31,039 | 18,993 | |
| Net working cap to sales | % | 44.8 | 37.0 | 56.7 | 25.0 | 20.6 | |
| Current ratio | x | 1.8 | 1.4 | 1.9 | 1.2 | 1.3 | |
| Inventory Days | Days | 48 | 63 | 78 | 97 | 71 | |
| Debtors Days | Days | 99 | 112 | 132 | 132 | 113 | |
| Net fixed assets | Rs m | 5,506 | 8,400 | 35,682 | 37,639 | 34,289 | |
| Share capital | Rs m | 596 | 596 | 894 | 894 | 895 | |
| "Free" reserves | Rs m | 4,594 | 10,962 | 25,685 | 26,594 | 23,651 | |
| Net worth | Rs m | 10,068 | 11,558 | 26,579 | 27,488 | 24,546 | |
| Long term debt | Rs m | 2,755 | 2,530 | 26,270 | 16,377 | 15,513 | |
| Total assets | Rs m | 20,990 | 24,805 | 74,559 | 81,050 | 65,437 | |
| Interest coverage | x | 2.1 | 4.3 | 2.2 | 3.1 | 1.7 | |
| Debt to equity ratio | x | 0.3 | 0.2 | 1.0 | 0.6 | 0.6 | |
| Sales to assets ratio | x | 0.6 | 0.5 | 0.4 | 0.3 | 0.4 | |
| Return on assets | % | 89.4 | 36.0 | 3.8 | 5.7 | 4.1 | |
| Return on equity | % | 175.5 | 73.1 | 4.4 | 10.2 | 2.9 | |
| Return on capital | % | 171.6 | 73.8 | 6.2 | 12.0 | 6.9 | |
| Exports to sales | % | 59.4 | 60.2 | 53.1 | 0 | 0 | |
| Imports to sales | % | 20.5 | 23.5 | 15.9 | 0 | 0 | |
| Exports (fob) | Rs m | 7,959 | 7,204 | 15,192 | 0 | 0 | |
| Imports (cif) | Rs m | 2,752 | 2,809 | 4,565 | 0 | 0 | |
| Fx inflow | Rs m | 22,791 | 13,031 | 16,612 | 13,465 | 15,697 | |
| Fx outflow | Rs m | 3,088 | 3,165 | 5,292 | 4,076 | 735 | |
| Net fx | Rs m | 19,703 | 9,865 | 11,320 | 9,389 | 14,962 | |
| STRIDES PHARMA SCIENCE CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | -2,717 | 834 | 733 | 2,881 | 1,871 | |
| From Investments | Rs m | 40,771 | 519 | -22,248 | -6,867 | 5,826 | |
| From Financial Activity | Rs m | -33,185 | -4,213 | 29,439 | 3,382 | -10,157 | |
| Net Cashflow | Rs m | 4,869 | -2,860 | 7,924 | -603 | -2,615 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Deepak Vaidya (MD) | COMP SEC: Badree Komandur (EVP-Finance) | YEAR OF INC: 1980 | BSE CODE: 532531 | FV (Rs): 10 | DIV YIELD (%): 0.8 |
Read: STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: J.B.CHEMICALS GSK PHARMA CIPLA PANACEA BIOTECH INDOCO REMEDIES
Compare STRIDES PHARMA SCIENCE With: J.B.CHEMICALS GSK PHARMA CIPLA PANACEA BIOTECH INDOCO REMEDIES
Compare STRIDES PHARMA SCIENCE With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Rising Crude Oil Prices, June Quarter Results, and Top Stocks in Action Today(Pre-Open)
On Friday, Indian share markets extended their decline for the 2nd day as markets witnessed a sharp sell-off amid disappointing earnings and slowing economic growth concerns.
Views on news
STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)
May 13, 2019 | Updated on May 13, 2019For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)
Jan 30, 2019 | Updated on Jan 30, 2019For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.
STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)
Dec 19, 2018 | Updated on Dec 19, 2018Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound (Profit Hunter)
Jul 9, 2019As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.
2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On... (The 5 Minute Wrapup)
Jul 12, 2019Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.
The Electric Vehicle Disruption is Great News for this Smallcap Stock (Profit Hunter)
Jul 15, 2019While big auto makers are finding the transition difficult and crying foul, this small cap company is already leading and benefitting from the electric vehicle disruption in the auto sector.
Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock (The 5 Minute Wrapup)
Jul 10, 2019Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.
7 Stocks to Profit From an Irreversible Trend (The 5 Minute Wrapup)
Jul 18, 2019Credit growth is likely to accelerate in India in the next decade. Here's how you can benefit from this megatrend.
More|
| |
TRACK STRIDES PHARMA SCIENCE
- Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON STRIDES PHARMA SCIENCE
STRIDES PHARMA SCIENCE 8-QTR ANALYSIS
COMPARE STRIDES PHARMA SCIENCE WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.